We are engaged in the business of distribution and supply within the pharmaceutical and consumer goods sectors, offering a comprehensive range of services. Our roles include being representatives, dealers, agents, stockists, suppliers, traders, and packers. We offer a wide range of products ... Read more
| Investors Category | Shares Offered |
|---|---|
| Market Makers | 2,84,000 (9.82%) |
| Non Institutional Investors | 26,08,000 (90.18%) |
| Retail Individual Investors (RIIs) | 26,08,000 (90.18%) |
| Year End | Revenue | PAT | Reserves & Surplus |
|---|---|---|---|
| 31 Mar 2025 | 107.59 Cr | 4.80 Cr | 18.14 Cr |
| 31 Mar 2024 | 54.34 Cr | 1.65 Cr | 0 |
| 31 Mar 2023 | 50.59 Cr | 18.16 Lakh | 0 |
1. Funding of capital expenditure requirements of our company towards the construction of Pharmaceutical API/ Intermediates and Chemicals manufacturing plant and purchase of new machineries in MIDC – Shrirampur, Ahmednagar, Maharashtra;
2. Repayment/prepayment of all or certain of our borrowings availed of by our Company
3. General corporate purposes
| Pricing Details | BSE | NSE |
|---|---|---|
| Issue Price | - | ₹ 35.00 |
| Open | - | ₹ 35.00 |
| Low | - | ₹ 35.00 |
| High | - | ₹ 36.75 |
| Last Trade | - | ₹ 35.90 |
Indian pharmaceutical industry is ranked as the third largest in the world, in terms of volumes of drugs manufactured and thirteenth largest, in terms of value. The Country is also the world’s largest supplier of cost-effective generic drugs, and accounts for nearly one fifth of the global ... Read more
When does VijayPD Ceutical Ltd. IPO opens and closes?
What is the size of VijayPD Ceutical Ltd. IPO?
What is the minimum investment and lot size required for the VijayPD Ceutical Ltd. IPO?
When is VijayPD Ceutical Ltd. IPO listing date?
What is the objective of VijayPD Ceutical Ltd. IPO?
Disclaimer: This is 3rd Party content/feed, viewers are requested to use their discretion and conduct proper diligence before investing, GoodReturns does not take any liability on the genuineness and correctness of the information in this article